DioGenix, Fast Forward Partner on NGS-based MDx for MS | GenomeWeb

NEW YORK (GenomeWeb News) – DioGenix announced today a collaboration with Fast Forward to develop a molecular diagnostic test for multiple sclerosis.

As part of the deal, Fast Forward, a subsidiary of the National Multiple Sclerosis Society, will provide DioGenix $500,000 to expand its ongoing clinical trial for MSPrecise, a diagnostic test based on next-generation sequencing to measure genetic mutations in the adaptive immune system by analyzing B cells isolated from cerebral spinal fluid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.